Morgan Stanley analyst Vikram Purohit maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $8.50.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vikram Purohit has given his Hold rating due to a combination of factors related to the recent acquisition offer for SAGE Therapeutics by Supernus Pharmaceuticals. The offer includes an upfront payment of $8.50 per share and a contingent value right (CVR) that could add up to $3.50 per share, depending on certain commercial milestones being met. This offer represents a significant premium over SAGE’s recent trading price and aligns closely with previous price targets.
Despite the attractive premium, Purohit’s Hold rating reflects uncertainties surrounding the realization of the CVR payments, which are contingent on achieving specific sales targets for Zurzuvae. Additionally, the likelihood of a competing bid is considered low due to the extensive strategic review process SAGE has undergone. These factors contribute to a cautious outlook, justifying the Hold recommendation as investors await further developments in the acquisition process.
In another report released yesterday, TD Cowen also maintained a Hold rating on the stock with a $8.50 price target.